HMGA2 overexpression in non-small cell lung cancer

Molecular Carcinogenesis

Volumn 46, Issue 7, 2007, Pages 503-511

  Meyer, Britta ^a   Loeschke, Siegfried ^a   Schultze, Anke ^a   Weigel, Thomas ^b   Sandkamp, Martin ^b   Goldmann, Torsten ^c   Vollmer, Ekkehard ^c   Bullerdiek, Jörn ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b Laboratory Dr M Sandkamp   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

Author keywords

HMGA2; Immunohistochemistry; Non small cell lung cancer; Quantitative real time RT PCR

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN;

ADULT; AGED; ARTICLE; FEMALE; GENE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HMGA2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34447532061     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20235     Document Type: Article

References (53)

1. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265:8573-8582.
2. Wolffe AP. Architectural transcription factors. Science 1994;264:1100-1101.
3. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996;54:35-100.
4. Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993;21:4259-4267.
5. Johnson KR, Lehn DA, Reeves R. Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 1989;9:2114-2123.
6. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 1995;10:436-444.
7. Chau KY, Patel UA, Lee KL, Lam HY, Crane-Robinson C. The gene for the human architectural transcription factor HMGI-C consists of five exons each coding for a distinct functional element. Nucleic Acids Res 1995;23:4262-4266.
8. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-2446.
9. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-779.
10. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350-357.
11. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999;25:316-322.
12. Boo LM, Lin HH, Chung V, et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005;65:6622-6630.
13. Adair JE, Kwon Y, Dement GA, Smerdon MJ, Reeves R. Inhibition of nucleotide excision repair by high mobility group protein HMGA1. J Biol Chem 2005.
14. Reeves R, Adair JE. Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair (Amst) 2005;4:926-938.
15. Baldassarre G, Belletti B, Battista S, et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 2005.
16. Hennig Y, Rogalla P, Wanschura S, et al. HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 1997;96:129-133.
17. Williams AJ, Powell WL, Collins T, Morton CC. HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol 1997;150:911-918.
18. Sornberger KS, Weremowicz S, Williams AJ, et al. Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 1999;114:9-16.
19. Kazmierczak B, Meyer-Bolte K, Tran KH, et al. A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer 1999;26:125-133.
20. Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S, Bullerdiek J. Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. J Natl Cancer Inst 1996;88:1234-1236.
21. Kazmierczak B, Bullerdiek J, Pham KH, Bartnitzke S, Wiesner H. Intron 3 of HMGIC is the most frequent target of chromosomal aberrations in human tumors and has been conserved basically for at least 30 million years. Cancer Genet Cytogenet 1998;103:175-177.
22. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275:14394-14400.
23. Battista S, Fidanza V, Fedele M, et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999;59:4793-4797.
24. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-774.
25. Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996;56:1896-1901.
26. Bussemakers MJ, van de Ven WJ, Debruyne FM, Schalken JA. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 1991;51:606-611.
27. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58:4193-4198.
28. Flohr AM, Rogalla P, Bonk U, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 2003;18:999-1004.
29. Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58:426-431.
30. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: Relationship to histologic grade. Mol Carcinog 1997;19:153-156.
31. Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 2003;89:2104-2109.
32. Rogalla P, Drechsler K, Schroder-Babo W, Eberhardt K, Bullerdiek J. HMGIC expression patterns in non-small lung cancer and surrounding tissue. Anticancer Res 1998;18:3327-3330.
33. Rommel B, Rogalla P, Jox A, et al. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 1997;26:603-607.
34. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64:2024-2029.
35. Gross KL, Neskey DM, Manchanda N, et al. HMGA2 expression in uterine leiomyomata and myometrium: Quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 2003;38:68-79.
36. Giancotti V, Pani B, D'Andrea P, et al. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. Embo J 1987;6:1981-1987.
37. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-4261.
38. Broers JL, Viallet J, Jensen SM, et al. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 1993;9:33-43.
39. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74:1862-1868.
40. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-3378.
41. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34:207-218.
42. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-1372.
43. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-1456.
44. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al. K-ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos. Int J Cancer 1993;53:250-256.
45. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-193.
46. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8:138-140.
47. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
48. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: From molecular mechanisms to clinical application. Clin Cancer Res 2004;10:3237-3248.
49. Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004;149:98-106.
50. Park IW, Wistuba II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999;91:1863-1868.
51. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-1373.
52. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002;122:1037-1057.
53. Langelotz C, Schmid P, Jakob C, et al. Expression of high-mobility-group- protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003;88:1406-1410.